Premium
The Relationship Between Plasminogen Activator Inhibitor‐1 and Insulin Resistance in Newly Diagnosed Type 2 Diabetes Mellitus
Author(s) -
Gough S.C.L.,
Rice P.J.S.,
McCormack L.,
Chapman C.,
Grant P.J.
Publication year - 1993
Publication title -
diabetic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 145
eISSN - 1464-5491
pISSN - 0742-3071
DOI - 10.1111/j.1464-5491.1993.tb00137.x
Subject(s) - medicine , insulin resistance , endocrinology , plasminogen activator inhibitor 1 , type 2 diabetes mellitus , plasminogen activator , diabetes mellitus , body mass index , insulin , type 2 diabetes , excretion , obesity , triglyceride , cholesterol
It is not clear whether elevated levels of the fibrinolytic inhibitor, plasminogen activator inhibitor‐1 (PAI‐1) in Type 2 diabetes mellitus are the result of obesity or coexistent atherosclerosis. Therefore the relationship between PAI‐1 and insulin resistance, determined by the homeostasis model assessment (HOMA) was investigated in a group of 26 insulin‐resistant, normotensive newly diagnosed Type 2 diabetic patients with a low probability of atherosclerosis. Compared with a normal control group, closely matched for body mass index (BMI), fibrinolytic activity was depressed in the diabetic patients due to elevated levels of the inhibitor PAI‐1, 17.6 (11.1–28) vs 8.4 (4.9–14.1) IU ml −1 , p < 0.001. PAI‐1 was related to BMI, r = 0.59, p < 0.001 plasma insulin, r =0.66, p < 0.001; insulin resistance, r = 0.54, p < 0.005 and urinary albumin excretion, r =0.48, p < 0.01, but not HbA 1c or fasting glucose. PAI‐1 was not related to blood pressure or plasma triglyceride levels. This study suggests that at the time of diagnosis of Type 2 diabetes mellitus, elevated PAI‐1 levels are already linked to other risk factors for vascular disease including hyperinsulinaemia, insulin resistance, and urinary albumin excretion, and this is not the result of obesity or coexistent atherosclerosis.